<DOC>
	<DOCNO>NCT00348504</DOCNO>
	<brief_summary>The primary objective study compare efficacy levosimendan dobutamine all-cause mortality 180 day follow randomization .</brief_summary>
	<brief_title>Survival Patients With Acute Heart Failure Need Intravenous Inotropic Support : Multicentre , Parallel-Group , Randomised , Double-Blind , Double-Dummy Study Levosimendan Versus Dobutamine Patients With Acute Heart Failure .</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<mesh_term>Dobutamine</mesh_term>
	<criteria>Written , sign date informed consent Male female patient 18 year age . Females childbearing potential must negative pregnancy test must refrain breastfeeding . Women postmenopausal [ two year since last menstrual cycle ] , surgically sterilise undergone hysterectomy consider childbearing potential Hospitalised patient acutely decompensated heart failure Left ventricular ejection fraction less equal 30 % assess use echocardiography , radionuclide ventriculography contrast angiography within 12 month Clinical need intravenous inotropic support evidence insufficient response intravenous diuretic and/or vasodilator ( nitroglycerin , nitroprusside ) least one follow screening : oliguria ( mean urine output &lt; 30 ml/h least 6 hour ) result hypovolemia dyspnoea rest mechanical ventilation heart failure haemodynamic impairment patient SwanGanz catheter insert ( PCWP ≥ 18 mmHg and/or Cardiac Index ≤ 2.2 l/min/m2 ) Severe obstruction ventricular outflow tract haemodynamically significant uncorrected primary valve disease hypertrophic cardiomyopathy impair ventricular fill restrictive cardiomyopathy Weight ≥ 160 kg Cardiac surgery within 30 day screen Stroke within 3 month screen Systolic blood pressure persistently less 85 mmHg screen baseline Heart rate persistently 130 bpm great screen baseline Serum potassium le 3.5 mmol/l screen Administration inotropic agent ( e.g . dobutamine , milrinone , amrinone , enoximone , epinephrine , norepinephrine ) except digitalis dopamine ( dose less equal 2 mg/kg/min ) current hospitalisation Hypersensitivity levosimendan dobutamine excipients A history Torsades de Pointes Severe renal insufficiency ( serum creatinine &gt; 450 mmol/l [ 5.0 mg/dl ] ) dialysis Significant hepatic impairment discretion investigator Acute bleeding Severe anemia ( haemoglobin &lt; 8 g/dl ) screen Septicaemia septic shock Other serious disease limit life expectancy considerably ( e.g . endstage cancer ) Participation clinical trial experimental treatment within 30 day prior screen previous participation present study Administration levosimendan within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>